2023
Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction
Butt J, Docherty K, Kosiborod M, Inzucchi S, Køber L, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Jhund P, McMurray J. Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction. JACC Heart Failure 2023, 11: 1411-1423. PMID: 37318419, DOI: 10.1016/j.jchf.2023.04.016.Peer-Reviewed Original ResearchConceptsKansas City Cardiomyopathy QuestionnaireActivity limitation scoresEffect of dapagliflozinLimitation scoresSocial activity limitationsHeart failureActivity limitationsDAPA-HF trialReduced ejection fractionProportion of patientsActivity limitation domainLimitation domainEjection fractionPhysical functionChronic diseasesDapagliflozinPatientsHealth statusPlaceboMixed-effects modelsMonthsBaselineComplete dataScoresSocial limitations
2022
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF
Adamson C, Welsh P, Docherty K, de Boer R, Diez M, Drożdż J, Dukát A, Inzucchi S, Køber L, Kosiborod M, Ljungman C, Martinez F, Ponikowski P, Sabatine M, Morrow D, Lindholm D, Hammarstedt A, Boulton D, Greasley P, Langkilde A, Solomon S, Sattar N, McMurray J, Jhund P. IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction Findings From DAPA-HF. JACC Heart Failure 2022, 11: 291-304. PMID: 36592046, DOI: 10.1016/j.jchf.2022.09.004.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor-binding protein 7IGFBP-7 levelsHeart failureN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideHigh-sensitivity troponin TCox proportional hazards modelBenefit of dapagliflozinDAPA-HF trialEjection fraction (EF) findingsIGFBP-7 concentrationsWorse clinical profileReduced ejection fractionAdverse clinical outcomesPotential prognostic biomarkerProportional hazards modelAdvanced HFrEFDAPA-HFCardiovascular deathHF outcomesNT-proBNPPrimary endpointClinical profileEjection fractionHighest tertileRelationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF
Yeoh S, Docherty K, Jhund P, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Solomon S, Sattar N, Welsh P, Sabatine M, Morrow D, McMurray J. Relationship between endothelin-1, heart failure with reduced ejection fraction and dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.833. DOI: 10.1093/eurheartj/ehac544.833.Peer-Reviewed Original ResearchBaseline ET-1 concentrationET-1 concentrationsBaseline ET-1Benefit of dapagliflozinSerum ET-1Kidney functionEndothelin-1Tertile 3NT-proBNPPrimary outcomeCirculating Endothelin-1DAPA-HF trialEfficacy of dapagliflozinET-1 measurementsHeart Failure TrialReduced ejection fractionWorse functional statusET-1 levelsHeart failure outcomesHeart failure severityHigh-sensitivity troponinDAPA-HFCardiovascular deathEGFR slopeLower eGFRStroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model
Kondo T, Jhund P, Abraham W, Rouleau J, Packer M, Desai A, Kober L, Solomon S, Zile M, Inzucchi S, Kosiborod M, Sabatine M, Ponikowski P, Martinez F, McMurray J. Stroke in patients with heart failure and reduced ejection fraction without atrial fibrillation: external validation of a risk model. European Heart Journal 2022, 43: ehac544.869. DOI: 10.1093/eurheartj/ehac544.869.Peer-Reviewed Original ResearchAtrial fibrillationHeart failureRisk scoreEjection fractionHistory of AFRisk/benefit profileBackground Heart failureCardio-embolic strokeDAPA-HF trialModern pharmacological therapyProphylactic anticoagulant therapyRisk/benefit balanceReduced ejection fractionRisk of strokeIdentification of patientsInsulin-treated diabetesProbability of strokePatient-level dataSimple risk modelStroke prediction modelsHFrEF patientsProphylactic anticoagulationHF patientsNT-proBNPPARADIGM-HFOutcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF
Adamson C, Welsh P, Morrow D, Docherty K, Hammarstedt A, Inzucchi S, Kober L, Kosiborod M, Martinez F, Ponikowski P, Sabatine M, Solomon S, Sattar N, Jhund P, McMurray J. Outcomes related to IGFBP-7 in patients with heart failure and reduced ejection fraction and effects of dapagliflozin: findings from DAPA-HF. European Heart Journal 2022, 43: ehac544.913. DOI: 10.1093/eurheartj/ehac544.913.Peer-Reviewed Original ResearchIGFBP-7 levelsAdjusted hazard ratioReduced ejection fractionEffect of dapagliflozinIGFBP-7NT-proBNPPrimary outcomeEjection fractionHeart failureDAPA-HFNYHA classCause mortalityHF eventsHighest thirdCorresponding adjusted hazard ratioMore type 2 diabetesHigh-sensitivity troponin TInsulin-like growth factor binding protein 7Growth factor binding protein 7Adverse HF outcomesBenefit of dapagliflozinDAPA-HF trialEfficacy of dapagliflozinHigher NYHA classNYHA class IIEffects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Docherty K, Anand I, Chiang C, Chopra V, Desai A, Kitakaze M, Verma S, Vinh P, Inzucchi S, Køber L, Kosiborod M, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjöstrand M, Solomon S, Langkilde A, Jhund P, McMurray J. Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia 2022, 2: 139-153. PMID: 36339117, PMCID: PMC9627879, DOI: 10.1016/j.jacasi.2022.02.004.Peer-Reviewed Original ResearchDAPA-HF trialReduced ejection fractionEjection fractionCardiovascular deathAsian patientsHF eventsElevated N-terminal pro-B-type natriuretic peptideNew York Heart Association functional class IIN-terminal pro-B-type natriuretic peptidePro-B-type natriuretic peptideLeft ventricular ejection fractionSafety of dapagliflozinFunctional class IIEffect of dapagliflozinVentricular ejection fractionDAPA-HFDrug discontinuationHFrEF patientsPrimary endpointAdverse eventsHeart failurePrespecified outcomesPrimary outcomeNatriuretic peptideSame extent
2020
CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL
Docherty K, Jackson A, Inzucchi S, Jhund P, Kober L, Kosiborod M, Langkilde A, Martinez F, Bengtsson O, Ponikowski P, Sabatine M, Sjoestrand M, Solomon S, Desai A, Diez M, Howlett J, Ljungman C, O'Meara E, Petrie M, Schou M, Pham V, McMurray J. CONSISTENT BENEFIT OF DAPAGLIFLOZIN ACCORDING TO BACKGROUND THERAPY IN PATIENTS WITH HFREF: AN ANALYSIS OF THE DAPA-HF TRIAL. Journal Of The American College Of Cardiology 2020, 75: 656. DOI: 10.1016/s0735-1097(20)31283-3.Peer-Reviewed Original Research